CoChat

Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C

Nielsen, Mette J., Veidal, Sanne S., Karsdal, Morten A., Ørsnes‐Leeming, Diana J., Vainer, Ben, Gardner, Stephen D., Hamatake, Robert, Goodman, Zachary D., Schuppan, Detlef, Patel, Keyur · 2015 · Liver International
Cited by 144

The DOI matches its Crossref record.

Abstract

Background & Aims: Fibrogenesis results in release of certain extracellular matrix protein fragments into the circulation. We evaluated the diagnostic and prognostic performance of two novel serological markers, the precisely cleaved N‐terminal propeptide of type III collagen (Pro‐C3) and a peptide of helical collagen type III degradation (C3M), in chronic hepatitis C (CHC) patients. Method: Pro‐C3 and C3M were measured by ELISA in plasma from CHC patients (n = 194) from a prior phase II antifibrotic trial (NCT 00244751). Plasma samples and paired liver biopsies were obtained at baseline and after 1‐year. Patients were stratified according to Ishak stages 2‐4. Internal cross‐validation was performed by bootstrap analysis. Results: Pro‐C3 levels were significantly higher in CHC patients in Ishak stage 4 compared to stage 2 (P < 0.001) or 3 (P < 0.01). Pro‐C3 could significantly distinguish moderate (stage 4) from mild fibrosis (stage 2/3) (AUC = 0.72, P < 0.001). Importantly, an overall significance in Pro‐C3 (P = 0.007) levels was observed between the groups of −1, 0, +1 and +2 change in Ishak stage at 12 months. Pro‐C3 was significantly increased in group +1 (P = 0.030) and +2 (P = 0.021) compared to group 0. No significant differences were observed for C3M. In multivariate analysis, only baseline Pro‐C3, but not FibroTest, had an independent association with fibrosis progression. Conclusions: Pro‐C3 is a useful test to predict fibrogenesis and monitor disease progression. Moreover, it could differentiate mild from moderate disease. Pro‐C3 may become a promising blood parameter be included in future studies for monitoring disease progression and eventually for evaluation of potential antifibrotic therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.12700

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 144

Metadata

Authors
Nielsen, M. J., Veidal, S. S., Karsdal, M. A., Ørsnes‐Leeming, D. J., Vainer, B., Gardner, S. D., Hamatake, R., Goodman, Z. D., Schuppan, D., & Patel, K.
Venue
Liver International
Publisher
Wiley
Published
2014-10-29
Volume
35
Issue
2
Pages
429-437
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2125971163
Cited by
144
References
0
FWCI
4.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. https://app.cochat.ai/papers/10.1111/liv.12700
The paper
Nielsen, M. J., Veidal, S. S., Karsdal, M. A., Ørsnes‐Leeming, D. J., Vainer, B., Gardner, S. D., Hamatake, R., Goodman, Z. D., Schuppan, D., & Patel, K. (2015). Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver International. https://doi.org/10.1111/liv.12700

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.